Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Gets Panel Date Seeking First A-Fib Ablation Catheter Indication

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson's chances of becoming the first firm to market an ablation device in the U.S. labeled for treating atrial fibrillation will be clearer next month, when the company is scheduled to present PMA supplement data to an FDA advisory panel
Advertisement

Related Content

American Heart Association News In Brief
Endocare And Galil Join Forces To Form One Cryosurgery Company
American Heart Association News In Brief
Procedure Slowdown, DoJ Probe Lowers Performance Outlook For AtriCure
Medtronic Warms To Cryoablation With $380 Million Acquisition Of CryoCath
Drug Rhythm-Control Failure Widens Opening For Ablation, Say Cardiologists
Drug Rhythm-Control Failure Widens Opening For Ablation, Say Cardiologists
CryoCor Sees Opportunity With A-Fib Ablation Label; Do Physicians Agree?
AF Ablation Devices Need Randomized Trials, Advisory Panel Tells FDA
FDA Dispute Panel Rebuffs Cardima’s Catheter A-Fib Claims
Advertisement
UsernamePublicRestriction

Register

MT026695

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel